We developed an oral chemotherapy platform delivering hydrophilic/hydrophobic anti-cancer drugs to treat pancreatic cancer. When the capsule dissolves in the small intestine, the ingredients induce a temporary acidic environment, where carbon dioxide bubbles are generated. The process assists self-assemblies of nanoemulsions, which results in better absorption and enhanced overall bioavailability.

The as-prepared drug delivery system enhances the dispersion of drugs in the small intestine and hence the overall bioavailability via self-emulsification. This technique has the potential to readily replace intravenous injection clinical treatment. Moreover, the system demonstrates the possibility of differentiation in the absorption and transport mechanisms, leading to distinct drug accumulation in the organs.

Pancreatic cancer is one of the deadliest cancers, characterized by extremely poor prognosis. The as-prepared oral capsules deliver a combination of anticancer drugs, which are intended to replace intravenous injections. The ingredients are FDA-approved and commonly found in natural foods. In addition, oral capsules have a higher patient compliance and a lower manufacturing cost. Hence the technique is valuable to the pharmaceutical industry.